Par files for IPO
This article was originally published in Scrip
Executive Summary
Par Pharmaceutical has filed a registration statement with the US Securities and Exchange Commission for an initial public offering of up to $100m. The Chestnut Ridge, New York company specializes in harder to make generics (or those that face complex regulatory challenges) and also has two branded specialty pharma products: the hormonal anticancer therapy Megace (megestrol acetate) and Nascobal (cyanocobalamin, USP) vitamin B